FML S.O.P. OINT Rx
Generic Name and Formulations:
Indications for FML S.O.P. OINT:
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop 2–4 times daily or small amount of ointment 1–3 times daily. May give every 4 hours for 1st 24–48 hrs. Reevaluate after 2 days.
Fungal, mycobacterial, viral (except herpes zoster), or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure in prolonged use. Avoid abrupt cessation. May mask or exacerbate infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ocular irritation, increased intraocular pressure with possible glaucoma, infrequent optic nerve damage, cataracts, delayed wound healing; systemic hypercorticoidism (rare).
Susp—5mL, 10mL, 15mL; Oint—3.5g; Forte—5mL, 10mL, 15mL
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight